Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913027 | 0.85 | CES2 (0.40) | CYP3A4CYP2C19CYP2C9CES2CES1 | |
| SCHEMBL17114310 | 0.84 | CYP3A4 (0.48) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL18650595 | 0.79 | MAP4K4 (0.38) | DHODH | |
| SCHEMBL17120565 | 0.75 | CES2 (0.42) | CYP2C19CES2CES1CYP1A2DHODH | |
| SCHEMBL22238272 | 0.75 | KDM4E (0.39) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11913026 | 0.70 | CYP3A4 (0.56) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL18655753 | 0.70 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL18650601 | 0.70 | CYP3A4 (0.46) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL18655741 | 0.70 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL20903514 | 0.70 | GAA (0.40) | CYP3A4CYP2C19CYP2C9CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081285-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081285-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C19 290/4885CYP2C9 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.